INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This is a phase II, randomized, open label, multi-center, parallel design, window of
opportunity trial in up to 60 patients with early stage breast cancer evaluating intratumoral
INT230-6.
Phase:
Phase 2
Details
Lead Sponsor:
Ottawa Hospital Research Institute
Collaborators:
Intensity Therapeutics, Inc. Ontario Institute for Cancer Research